Home / NERV : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does NERV make money? Does NERV have pricing power? What's the Earnings Whisper? Will NERV profit more as the business scales? What is NERV's management track record? Is NERV's current price justified?

Minerva Neurosciences, Inc.

$4.15 +$0.23 (+5.87%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$4.16

Day Range

$4.13$4.37

Year Range

$1.93$12.46

Market Cap

193.34M

AVG Volume

217.84K

Trailing/Forward PE

-0.15/-

PEG ratio

Dividend Yield

Next Earnings Date

2026-11-04

Primary Exchange

NASDAQ

Revenue (USD) · TTM

NERV Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	0
26 Q1	0
25 Q4	0
25 Q3	0
25 Q2	0
25 Q1	0
24 Q4	0
24 Q3	0
24 Q2	0
24 Q1	0

Net Income (USD) · TTM

NERV Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-394.35M
26 Q1	-415.07M
25 Q4	-293.42M
25 Q3	-14.03M
25 Q2	11.23M
25 Q1	6.25M
24 Q4	1.44M
24 Q3	-3.31M
24 Q2	-33.65M
24 Q1	-31.6M

Operating Income (USD) · TTM

NERV Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-35.14M
26 Q1	-27.87M
25 Q4	-15.1M
25 Q3	-14.64M
25 Q2	-16.17M
25 Q1	-19.07M
24 Q4	-21.85M
24 Q3	-24.5M
24 Q2	-26.21M
24 Q1	-24.45M

EBITDA (USD) · TTM

NERV EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-394.35M
26 Q1	-415.07M
25 Q4	-293.42M
25 Q3	-14.02M
25 Q2	11.24M
25 Q1	8.58M
24 Q4	6.02M
24 Q3	3.47M
24 Q2	-24.78M
24 Q1	-23.02M

Cash Flows (USD) · TTM

NERV Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-18.78B
26 Q1	-5.44B
24 Q4	-19.55M
24 Q3	-20.38M
24 Q2	-20.83M
24 Q1	-20.76M
23 Q4	-14.78M
23 Q3	-12.92M
23 Q2	-17.65M
23 Q1	-18.97M

EPS (USD) · TTM

NERV EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-28.87
26 Q1	-29.16
25 Q4	-26.8
25 Q3	-1.85
25 Q2	1.48
25 Q1	0.82
24 Q4	0.19
24 Q3	-0.44
24 Q2	-4.44
24 Q1	-4.47

Expenses (USD) · TTM

NERV Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
23 Q4	0
23 Q3	0
23 Q2	-2.13K
23 Q1	-2.13K
26 Q2	16.69B
26 Q1	16.68B
25 Q4	15.1M
25 Q3	14.64M
25 Q2	16.17M
25 Q1	19.07M
24 Q4	21.85M
24 Q3	24.5M
24 Q2	26.21M
24 Q1	24.45M

Shares Outstanding (USD) · TTM

NERV Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-10.98B
26 Q1	-8.71B
24 Q4	-1.33M
24 Q3	-1.69M
24 Q2	-1.75M
24 Q1	-2.03M
23 Q4	-1.97M
23 Q3	-2.31M
23 Q2	-2.97M
23 Q1	-3.43M

Employee Count

NERV Employee Count by quarter
Period	Employee Count
2025	7
2024	8
2023	9
2022	9
2021	9
2020	11
2019	13
2018	13
2017	12
2016	11

PE Ratio

NERV PE Ratio by quarter
Period	PE Ratio
Oct 25	2.83
Oct 25	3.17
Oct 25	1.68
Oct 25	1.58
Oct 25	1.42
Sep 25	1.43
Sep 25	1.37
Sep 25	1.47
Sep 25	1.58
Aug 25	1.59
Aug 25	1.64
Aug 25	1.52
Aug 25	2.13
Aug 25	2.31
Jul 25	2.58
Jul 25	2.41
Jul 25	2.03
Jul 25	2
Jun 25	2.15
Jun 25	2.14
Jun 25	2.18
Jun 25	2.23
May 25	1.86
May 25	1.77
May 25	1.82
May 25	8.47
May 25	8.94
Apr 25	9.26
Apr 25	8.42
Apr 25	7.63
Apr 25	7.21
Mar 25	9.52
Mar 25	9.47
Mar 25	8.1
Mar 25	8.63
Feb 25	8.78
Jul 21	14.87
Jul 21	15.68
Jul 21	15.6
Jul 21	18.18
Jul 21	18.75
Jun 21	19.96
Jun 21	21.25
Jun 21	23.43
Jun 21	23.43
May 21	23.84
May 21	25.13
May 21	23.68
May 21	48.82
Apr 21	51.42
Apr 21	54.66
Apr 21	54.87
Apr 21	57.68
Apr 21	64.16
Mar 21	63.08
Mar 21	65.89
Mar 21	72.16

Free Cash Flow Yield

NERV Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-9710.77%
Sep 26	-9097%
Aug 26	-8326.39%
Aug 26	-8326.39%
Aug 26	-8799.06%
Aug 26	-9437.87%
Jul 26	-3111.52%
Jul 26	-3065.31%
Jul 26	-2900.2%
Jul 26	-2623.69%
Jul 26	-2428.2%
Jun 26	-2833.83%
Jun 26	-2770.43%
Jun 26	-2745.86%
Jun 26	-2496.74%
May 26	-2522.17%
May 26	-2354.34%
May 26	-2376.94%
May 26	-2106.09%
May 25	-160.43%
May 25	-151.94%
Apr 25	-146.76%
Apr 25	-161.44%
Apr 25	-178.14%
Apr 25	-188.54%
Mar 25	-142.71%
Mar 25	-143.5%
Mar 25	-167.73%
Mar 25	-157.5%
Feb 25	-154.67%
Feb 25	-147.91%
Feb 25	-136.65%
Feb 25	-121.26%
Jan 25	-116.53%
Jan 25	-124.63%
Jan 25	-120.71%
Jan 25	-124.05%
Jan 25	-118.07%
Dec 24	-119.11%
Dec 24	-124.63%
Dec 24	-121.81%
Dec 24	-119.11%
Nov 24	-119.11%
Nov 24	-120.18%
Nov 24	-122.36%
Nov 24	-115.04%
Nov 24	-105.03%
Oct 24	-112.78%
Oct 24	-109.64%
Oct 24	-105.44%
Oct 24	-105.03%
Sep 24	-101.92%
Sep 24	-97.58%
Sep 24	-93.28%
Sep 24	-105.44%
Aug 24	-100.43%
Aug 24	-104.63%
Aug 24	-107.92%
Aug 24	-95.55%
Aug 24	-94.59%
Jul 24	-89.65%
Jul 24	-87.36%
Jul 24	-80.92%
Jul 24	-88.49%
Jun 24	-86%
Jun 24	-79.75%
Jun 24	-82.38%
Jun 24	-85.19%
May 24	-107.58%
May 24	-112.43%
May 24	-108.86%
May 24	-114.78%
May 24	-115.75%
Apr 24	-80.05%
Apr 24	-78.76%
Apr 24	-78.13%
Apr 24	-76.9%
Mar 24	-75.71%
Mar 24	-73.16%
Mar 24	-70.01%
Mar 24	-69.76%
Mar 24	-74.27%
Feb 24	-28.43%
Feb 24	-20.34%
Feb 24	-16.52%
Feb 24	-18.08%
Jan 24	-20.97%
Jan 24	-22.67%
Jan 24	-22.91%
Jan 24	-27.53%
Dec 23	-27.75%
Dec 23	-24.96%
Dec 23	-26.46%
Dec 23	-27.09%
Dec 23	-23.54%
Nov 23	-33.53%
Nov 23	-32.7%
Nov 23	-41.63%
Nov 23	-58.11%
Oct 23	-76.24%

Price to Sales

NERV Price to Sales by quarter
Period	Price to Sales
Jul 21	1.91
Jul 21	2.01
Jul 21	2
Jul 21	2.33
Jul 21	2.41
Jun 21	2.56
Jun 21	2.73
Jun 21	3.01
Jun 21	3.01
May 21	3.06
May 21	3.23
May 21	3.04
May 21	2.3
Apr 21	2.42
Apr 21	2.58
Apr 21	2.59
Apr 21	2.72
Apr 21	3.02
Mar 21	2.97
Mar 21	3.11
Mar 21	3.4
Mar 21	2.91
Feb 21	3.16
Feb 21	3.65
Feb 21	3.58
Feb 21	3.47
Jan 21	3.25
Jan 21	3.34
Jan 21	2.76
Jan 21	2.63
Dec 20	2.38
Dec 20	2.5
Dec 20	2.63
Dec 20	2.66
Dec 20	2.79
Nov 20	4.08
Nov 20	3.75
Nov 20	3.62
Nov 20	3.51
Oct 20	3.08
Oct 20	3.15
Oct 20	3.18
Oct 20	3.35
Oct 20	3.01
Sep 20	3.05
Sep 20	3.42
Sep 20	2.75
Sep 20	2.8
Aug 20	3.05
Aug 20	3.08
Aug 20	3.25
Aug 20	3.44

EV/EBITDA

NERV EV/EBITDA by quarter
Period	EV/EBITDA
Oct 25	1.47
Oct 25	1.81
Oct 25	0.32
Oct 25	0.23
Oct 25	0.06
Sep 25	0.07
Sep 25	0.01
Sep 25	0.11
Sep 25	0.23
Aug 25	0.23
Aug 25	0.29
Aug 25	0.16
Aug 25	-0.46
Aug 25	-0.33
Jul 25	-0.14
Jul 25	-0.26
Jul 25	-0.53
Jul 25	-0.56
Jun 25	-0.44
Jun 25	-0.45
Jun 25	-0.43
Jun 25	-0.39
May 25	-0.66
May 25	-0.73
May 25	-0.69
May 25	-1.52
May 25	-1.41
Apr 25	-1.33
Apr 25	-1.54
Apr 25	-1.72
Apr 25	-1.82
Mar 25	-1.27
Mar 25	-1.28
Mar 25	-1.61
Mar 25	-1.49
Feb 25	-1.45
Feb 25	-3.68
Feb 25	-3.35
Feb 25	-2.8
Jan 25	-2.61
Jan 25	-2.93
Jan 25	-2.78
Jan 25	-2.91
Jan 25	-2.67
Dec 24	-2.72
Dec 24	-2.93
Dec 24	-2.82
Dec 24	-2.72
Nov 24	-2.72
Nov 24	-2.76
Nov 24	-2.85
Nov 24	-2.54
Jul 21	-0.22
Jul 21	0.42
Jul 21	0.35
Jul 21	2.38
Jul 21	2.82
Jun 21	3.77
Jun 21	4.79
Jun 21	6.5
Jun 21	6.5
May 21	6.81
May 21	7.83
May 21	6.69
May 21	33.09
Apr 21	35.49
Apr 21	38.48
Apr 21	38.68
Apr 21	41.28
Apr 21	47.26
Mar 21	46.27
Mar 21	48.86
Mar 21	54.65

Price/Operating Cashflow

NERV Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Apr 18	80.44
Apr 18	90.14
Apr 18	86.38
Apr 18	85.13
Mar 18	78.24
Mar 18	80.12
Mar 18	78.87
Mar 18	76.39
Mar 18	69.09
Feb 18	73.74
Feb 18	72.41
Feb 18	73.74
Feb 18	82.37
Jan 18	87.69
Jan 18	90.34
Jan 18	83.04
Jan 18	79.72
Dec 17	80.38
Dec 17	80.38
Dec 17	79.05
Dec 17	75.73
Dec 17	73.74
Nov 17	71.08
Nov 17	69.09
Nov 17	69.09

Price to Book

NERV Price to Book by quarter
Period	Price to Book
Apr 22	2.73
Apr 22	3.54
Apr 22	4.17
Apr 22	4.36
Apr 22	4.66
Mar 22	4.34
Mar 22	4.23
Mar 22	3.7
Mar 22	3.59
Feb 22	1.04
Feb 22	1.13
Feb 22	1.11
Feb 22	1.14
Jan 22	1.1
Jan 22	1.28
Jan 22	1.27
Jan 22	1.29
Dec 21	1.22
Dec 21	1.47
Dec 21	1.41
Dec 21	1.38
Dec 21	1.41
Nov 21	1.61
Nov 21	1.7
Nov 21	1.99
Nov 21	1.59
Oct 21	1.65
Oct 21	1.5
Oct 21	1.59
Oct 21	1.69
Oct 21	1.87
Sep 21	2.41
Sep 21	2.01
Sep 21	1.97
Sep 21	2.11
Aug 21	2.23
Aug 21	2.16
Aug 21	2
Aug 21	2.16
Jul 21	1.73
Jul 21	1.83
Jul 21	1.82
Jul 21	2.12
Jul 21	2.18
Jun 21	2.33
Jun 21	2.48
Jun 21	2.73
Jun 21	2.73
May 21	2.78
May 21	2.93
May 21	2.76
May 21	1.8
Apr 21	1.89
Apr 21	2.01
Apr 21	2.02
Apr 21	2.13
Apr 21	2.36
Mar 21	2.32
Mar 21	2.43
Mar 21	2.66
Mar 21	2.07
Feb 21	2.24
Feb 21	2.59
Feb 21	2.54
Feb 21	2.46
Jan 21	2.3
Jan 21	2.37
Jan 21	1.96
Jan 21	1.86
Dec 20	1.69
Dec 20	1.78
Dec 20	1.86
Dec 20	1.89
Dec 20	1.98
Nov 20	2.9
Nov 20	2.66
Nov 20	2.57
Nov 20	2.49
Oct 20	2.23
Oct 20	2.28
Oct 20	2.3
Oct 20	2.42
Oct 20	2.18
Sep 20	2.2
Sep 20	2.48
Sep 20	1.99
Sep 20	2.02
Aug 20	2.2
Aug 20	2.23
Aug 20	2.35
Aug 20	2.49
Jul 20	7.33
Jul 20	7.49
Jul 20	7.58
Jul 20	7.17
Jul 20	7.49
Jun 20	7.36
Jun 20	7.43
Jun 20	7.17
Jun 20	8.25

No video analysis for this stock yet. Request one from our team.

News: NERV

globenewswire.com · 28 Aug 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

defenseworld.net · 17 Aug 2026

Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50

Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) has been assigned an average rating of "Reduce" from the four brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has given a buy recommendation to the company.

globenewswire.com · 7 Aug 2026

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended June 30, 2026.